Concise Prescribing Info
Inhibition of physiological lactation soon after parturition; suppression of established lactation. Hyperprolactinaemic disorders.
Dosage/Direction for Use
Inhibition of physiological lactation 1 mg as single dose during 1st postpartum day. Suppression of established lactation 0.25 mg every 12 hr for 2 days. Hyperprolactinaemic disorders Initially 0.5 mg/wk in 1 or 2 doses, may be increased gradually by adding 0.5 mg/wk at mthly intervals. Therapeutic range: 0.25-2 mg/wk.
Should be taken with food.
Hypersensitivity to cabergoline or any ergot alkaloid. History of pulmonary, pericardial & retroperitoneal fibrotic disorders. Long-term treatment, cardiac valvulopathy of any value as determined by pre-treatment ECG showing valve leaflet thickening, restriction & mixed restriction stenosis.
Special Precautions
Not to be used in patients w/ history of, current signs &/or clinical symptoms of resp or cardiac disorders linked to fibrotic tissue. Severe CV disease, Raynaud's syndrome, peptic ulcer, GI bleeding, history of serious (particularly psychotic) mental disorders; postural hypotension. Pleuro-pulmonary disease eg, dyspnea, shortness of breath, persistent cough or chest pain; urethral/abdominal vascular obstruction; cardiac failure. Somnolence/sudden sleep onset in Parkinson's disease. Psychiatric disorders. Perform CV evaluation, measure erythrocyte sedimentation rate, serum creatinine measurements, lung function/chest X-ray & renal function, complete pituitary evaluation prior to therapy. Concomitant use w/ drugs lowering BP. May affect ability to drive & use machines. Renal & severe hepatic insufficiency. Not to be used in women w/ pregnancy-induced HTN (eg, preeclampsia or postpartum HTN). Avoid use during pregnancy. Not to be used during lactation. Childn <16 yr. Elderly w/ hyperprolactinemic disorders.
Adverse Reactions
Dizziness/vertigo, nausea, headache, abdominal pain, vomiting, asthenia, hot flushes. Inhibition or suppression of lactation: Somnolence, palpitations, epigastric pain, epistaxis & transient hemianopsia, syncope. Hyperprolactinemic disorders: Dyspepsia/gastritis, fatigue, constipation, breast pain, depression & paresthesia.
Drug Interactions
Not recommended w/ other ergot alkaloids. Reduced prolactin-lowering effect w/ drugs having dopamine antagonist activity (eg, phenothiazines, butyrophenones, thioxanthenes, metoclopramide). Increased systemic bioavailability w/ macrolide antibiotics (eg, erythromycin).
MIMS Class
Oestrogens, Progesterones & Related Synthetic Drugs
ATC Classification
G02CB03 - cabergoline ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
Dostinex tab 0.5 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in